Vitamin D Supplementation in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Overview

Journal JGH Open

Specialty Gastroenterology

Date 2018 Nov 29

PMID 30483536

Citations 18

Authors

Mallikarjun Sakpal

Sandeep Satsangi

Manu Mehta

Ajay Duseja

Sanjay Bhadada

Ashim Das

Radha K Dhiman

Yogesh K Chawla

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Deficiency of vitamin D may be related to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the effect of vitamin D supplementation in patients with NAFLD.

Methods: A total of 81 patients with NAFLD with normal or raised ( = 47) serum alanine aminotransferase (ALT) having vitamin D deficiency were randomized prospectively. Group 1 ( = 51) received lifestyle modifications and a single injection of vitamin D (600 000 U) (standard medical treatment [SMT] + vitamin D) and group 2 ( = 30) received lifestyle modifications (SMT) for 6 months. The primary objective of this study was to assess the improvement in insulin resistance (IR) and serum ALT (in patients with raised ALT) and the secondary objective was to assess the change in cytokine profile in the SMT + vitamin D group.

Results: After 6 months, significant improvement in serum levels of ALT was observed in the SMT + vitamin D group when compared to the SMT group (ALT [87 ± 48 and 59 ± 32 IU/mL, < 0.001] [64 ± 35 and 62 ± 24 IU/mL, = 0.70]). Mean insulin levels and homeostasis model assessment-IR remained unchanged at 6 months in the SMT + vitamin D group while there was a significant increase in mean insulin and homeostasis model assessment-IR in the SMT group. SMT + vitamin D group had significant increase in mean serum levels of adiponectin (836 ± 309 and 908 ± 312 (pg/mL), = 0.018) compared with the baseline; tumor necrosis factor-α levels decreased from baseline but the change was not significant.

Conclusion: Patients with NAFLD given vitamin D in addition to lifestyle modifications have significant improvement in serum ALT and serum adiponectin levels.

Citing Articles

Vitamin D 1,25-Dihydroxyvitamin D reduces lipid accumulation in hepatocytes by inhibiting M1 macrophage polarization.

Luo W, Dong X, Ye H, Zhao Q, Zhang Q, Guo W World J Gastrointest Oncol. 2024; 16(12):4685-4699.

PMID: 39678811 PMC: 11577380. DOI: 10.4251/wjgo.v16.i12.4685.

Natural Products as Hepatoprotective Agents-A Comprehensive Review of Clinical Trials.

Sluzaly P, Pasko P, Galanty A Plants (Basel). 2024; 13(14).

PMID: 39065511 PMC: 11280762. DOI: 10.3390/plants13141985.

Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial.

Ebrahimpour-Koujan S, Sohrabpour A, Giovannucci E, Vatannejad A, Esmaillzadeh A Nutr J. 2024; 23(1):24.

PMID: 38413933 PMC: 10898146. DOI: 10.1186/s12937-024-00911-x.

The Role of Vitamin D in Obese Children with Non-Alcoholic Fatty Liver Disease and Associated Metabolic Syndrome.

Stepan M, Vintilescu S, Streata I, Podeanu M, Florescu D Nutrients. 2023; 15(9).

PMID: 37432275 PMC: 10181433. DOI: 10.3390/nu15092113.

The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial.

Mohamed A, Halim A, Mohamed S, Mahmoud S, Bahgat Eldemiry E, Sobh Mohamed R Front Pharmacol. 2023; 14:1149967.

PMID: 36998617 PMC: 10043211. DOI: 10.3389/fphar.2023.1149967.

References

Pittas A, Lau J, Hu F, Dawson-Hughes B . The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007; 92(6):2017-29. PMC: 2085234. DOI: 10.1210/jc.2007-0298. View

Jablonski K, Jovanovich A, Holmen J, Targher G, McFann K, Kendrick J . Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2013; 23(8):792-8. PMC: 3659172. DOI: 10.1016/j.numecd.2012.12.006. View

Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G . Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2006; 17(7):517-24. DOI: 10.1016/j.numecd.2006.04.002. View

Harinarayan C, Ramalakshmi T, Prasad U, Sudhakar D, Srinivasarao P, Sarma K . High prevalence of low dietary calcium, high phytate consumption, and vitamin D deficiency in healthy south Indians. Am J Clin Nutr. 2007; 85(4):1062-7. DOI: 10.1093/ajcn/85.4.1062. View

Dhiman R, Duseja A, Chawla Y . Asians need different criteria for defining overweight and obesity. Arch Intern Med. 2005; 165(9):1069-70. DOI: 10.1001/archinte.165.9.1069-b. View

Agrawal S, Duseja A . Nonalcoholic Fatty Liver Disease--The Clinician's Perspective. Trop Gastroenterol. 2015; 35(4):212-21. DOI: 10.7869/tg.219. View

Musso G, Gambino R, Cassader M, Pagano G . Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2010; 43(8):617-49. DOI: 10.3109/07853890.2010.518623. View

Gordon C, DePeter K, Feldman H, Grace E, Emans S . Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004; 158(6):531-7. DOI: 10.1001/archpedi.158.6.531. View

Kapil S, Duseja A, Sharma B, Singla B, Chakraborti A, Das A . Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2015; 31(1):213-21. DOI: 10.1111/jgh.13058. View

10.

Nakano T, Cheng Y, Lai C, Hsu L, Chang Y, Deng J . Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol. 2010; 55(2):415-25. DOI: 10.1016/j.jhep.2010.11.028. View

11.

Chow E, Maeng H, Liu S, Khan A, Groothuis G, Pang K . 1alpha,25-Dihydroxyvitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm Drug Dispos. 2009; 30(8):457-75. DOI: 10.1002/bdd.682. View

12.

Sanyal A . AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5):1705-25. DOI: 10.1053/gast.2002.36572. View

13.

Chitturi S, Abeygunasekera S, Farrell G, Holmes-Walker J, Hui J, Fung C . NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35(2):373-9. DOI: 10.1053/jhep.2002.30692. View

14.

Duseja A, Sharma B, Kumar A, Kapil S, Das A, Dhiman R . Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology. 2010; 52(6):2248-9. DOI: 10.1002/hep.23838. View

15.

Sachan A, Gupta R, Das V, Agarwal A, Awasthi P, Bhatia V . High prevalence of vitamin D deficiency among pregnant women and their newborns in northern India. Am J Clin Nutr. 2005; 81(5):1060-4. DOI: 10.1093/ajcn/81.5.1060. View

16.

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

17.

Vaidya A, Williams J, Forman J . The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: the NHS and the HPFS. Obesity (Silver Spring). 2011; 20(1):186-91. PMC: 3461263. DOI: 10.1038/oby.2011.210. View

18.

Geier A . Shedding new light on vitamin D and fatty liver disease. J Hepatol. 2011; 55(2):273-5. DOI: 10.1016/j.jhep.2010.12.026. View

19.

Pinelli N, Jaber L, Brown M, Herman W . Serum 25-hydroxy vitamin d and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care. 2010; 33(6):1373-5. PMC: 2875457. DOI: 10.2337/dc09-2199. View

20.

Choo V . WHO reassesses appropriate body-mass index for Asian populations. Lancet. 2002; 360(9328):235. DOI: 10.1016/S0140-6736(02)09512-0. View